证券代码：601607 证券简称：上海医药 编号：临 2025-080 上海医药集团股份有限公司 关于盐酸维拉帕米注射液通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"公司"）下属上海禾丰制药 有限公司（以下简称"上药禾丰"）的盐酸维拉帕米注射液（以下简称"该药品"） 收到国家药品监督管理局（以下简称"国家药监局"）颁发的《药品补充申请批 准通知书》（通知书编号：2025B03892），该药品通过仿制药质量和疗效一致 性评价。 规格：2ml:5mg 注册分类：化学药品 申请人：上海禾丰制药有限公司 药品批准文号：国药准字 H31021343 审批结论：本品通过仿制药质量和疗效一致性评价。 二、该药品相关的信息 盐酸维拉帕米注射液主要用于：1．快速阵发性室上性心动过速的转复。应 用维拉帕米之前应首选抑制迷走神经的手法治疗（如 Valsalva 法）。2．心房扑 动或心房颤动心室率的暂时控制。心房扑动或心房颤动合并房室旁路通道（预激 综合症和 LGL 综合 ...

人民财讯9月1日电，上海医药（601607）9月1日晚间公告，近日，公司下属上海禾丰制药有限公司的盐 酸维拉帕米注射液收到国家药监局颁发的《药品补充申请批准通知书》，该药品通过仿制药质量和疗效 一致性评价。 该药品主要用于：1．快速阵发性室上性心动过速的转复。应用维拉帕米之前应首选抑制迷走神经的手 法治疗。2．心房扑动或心房颤动心室率的暂时控制。心房扑动或心房颤动合并房室旁路通道（预激综 合症和LGL综合症）时除外。 ...

Overview - The pharmaceutical manufacturing industry in China is experiencing robust demand due to an aging population, rising chronic disease incidence, and increased public health awareness [1][5] - By 2024, the number of large-scale pharmaceutical manufacturing enterprises in China is projected to reach 9,793, with total assets of 51,746.1 billion yuan, sales revenue of 25,298.5 billion yuan, and total profits of 3,420.7 billion yuan [1][5] - The normalization of centralized procurement is driving traditional pharmaceutical companies to shift from "scale expansion" to "lean survival," promoting the construction of a lean management system across the entire industry chain [1][5] Industry Classification - The pharmaceutical manufacturing industry can be divided into eight sub-sectors: chemical raw materials, chemical preparations, traditional Chinese medicine processing, traditional Chinese medicine production, veterinary medicine, biological products, sanitary materials, and pharmaceutical packaging [2] Development History - The industry has evolved from a weak foundation in the early years of the People's Republic of China, primarily relying on imported raw materials, to a rapidly expanding sector with significant improvements in manufacturing standards [3] - Key milestones include the establishment of the National Medical Products Administration in 1998 and the introduction of various policies to encourage innovation and improve drug quality [3][4] Development Background - The industry is supported by numerous policies aimed at correcting irregularities in the pharmaceutical procurement and medical service sectors, promoting digital traditional Chinese medicine, and enhancing the quality of traditional Chinese medicine [4][5] - The aging population is projected to reach 22,023 million by 2024, with a 1.60% year-on-year increase, leading to a growing demand for chronic disease medications [5][6] Industry Chain - The upstream of the pharmaceutical manufacturing industry includes suppliers of chemical raw materials, traditional Chinese medicine materials, and pharmaceutical packaging [6] - The midstream consists of pharmaceutical manufacturing companies, while the downstream includes medical institutions, health service organizations, pharmacies, and e-commerce platforms [6] Current Development Status - The pharmaceutical market's rigid demand is continuously expanding, with significant growth in the number of medical institutions and healthcare spending per capita [1][7] - By 2024, the number of healthcare institutions in China is expected to reach 1,092,000, with hospitals and grassroots medical institutions showing steady growth [7] Competitive Landscape - The pharmaceutical manufacturing industry is characterized by a diverse market with numerous participants, but recent reforms have led to increased concentration among leading companies [8] - Major players include China National Pharmaceutical Group, China Resources Pharmaceutical Group, and Shanghai Fosun Pharmaceutical, which have strong financial and R&D capabilities [8][9] Future Development Trends - The normalization of centralized procurement is expected to narrow profit margins for traditional generic drugs, prompting companies to increase investment in innovative drugs and high-barrier generics [10] - Pharmaceutical companies will focus on self-research and global collaboration, particularly in high-demand therapeutic areas like oncology and autoimmune diseases, while optimizing their supply chain management to reduce costs [10]

Core Viewpoint - Shanghai Pharmaceuticals Group Co., Ltd. reported a steady growth in revenue and profit for the first half of 2025, driven by its innovative transformation and strong performance in both pharmaceutical manufacturing and commercial sectors [2][3]. Company Overview and Key Financial Indicators - The company achieved operating revenue of CNY 141.59 billion, a year-on-year increase of 1.56% [3]. - Total profit reached CNY 6.82 billion, reflecting a significant growth of 41.45% compared to the previous year [3]. - Net profit attributable to shareholders was CNY 4.46 billion, up 51.56% year-on-year [3]. - The company’s net assets amounted to CNY 75.10 billion, a 4.77% increase from the end of the previous year [3]. Business and Operational Highlights - The company focuses on pharmaceutical manufacturing and commercial operations, emphasizing innovation and efficiency [3][4]. - It is the second-largest pharmaceutical commercial enterprise in China, with a comprehensive distribution network covering 25 provinces [3][4]. - The company has established strategic partnerships with major domestic and international pharmaceutical manufacturers, enhancing its supply chain capabilities [3][4]. Industry Context - The biopharmaceutical industry in China is recognized as a strategic sector, crucial for national health and security, and is currently undergoing significant structural adjustments [3][4]. - Government policies are aimed at encouraging innovation, optimizing procurement rules, and improving medical insurance payments, which are expected to drive market growth [3][4]. Research and Development - The company invested CNY 1.15 billion in R&D, accounting for 9.44% of its pharmaceutical manufacturing revenue [4][5]. - A total of 56 new drug applications were accepted for clinical trials, including 44 innovative drug projects [4][5]. - The company is advancing several key projects in various therapeutic areas, including hypertension and neurodegenerative diseases [5][6]. Commercial Strategy - The company is enhancing its digital transformation and supply chain efficiency, aiming to provide integrated healthcare solutions [12][13]. - It has launched a new retail strategy that combines traditional and online sales channels, achieving significant growth in e-commerce sales [12][13]. - The company has established a comprehensive import service system, increasing its sales revenue from imported products by 11.7% [12][13]. Corporate Governance and Investor Relations - The company emphasizes long-term stable cash dividends and shareholder returns, having distributed CNY 1.37 billion in dividends for the previous year [15][16]. - It has implemented governance improvements in line with regulatory requirements, including the addition of a female independent director [16][17]. - The company maintains strong communication with investors, ensuring transparency and engagement through various channels [17][18].

| | 上海医药集团股份有限公司2025 | 年半年度报告摘要 | | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 公司 A | 股代码：601607 | 公司简称：上海医药 | | | | | | | | | | | | | H 公司 股代码：02607 | | 公司简称：上海醫藥 | | | | | | | | | | | | | | 上海医药集团股份有限公司 | | | | | | | | | | | | | | | 上海医药集团股份有限公司2025 | 年半年度报告摘要 | | | | | | | | | | | | | | 第一节 重要提示 | | | | | | | | | | | | | | 展规划，投资者应当到 | http://www.sse.com.cn | http://www.hkexnews.hk 网站仔细阅读半年度报告 | | | | | | | | | | | | | 全文。 | | | | | | | | | ...

证券代码：601607 证券简称：上海医药 公告编号：临2025-079 上海医药集团股份有限公司 第八届董事会第二十四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 一、董事会会议召开情况 关联/连董事杨秋华先生主动回避该议案的表决，八位非关联/连董事全部投 票同意。 表决结果：赞成 8 票，反对 0 票，弃权 0 票 特此公告。 上海医药集团股份有限公司 上海医药集团股份有限公司（以下简称"本公司"或"上海医药"）第八届 董事会第二十四次会议（以下简称"本次会议"）于 2025 年 8 月 28 日在上海市 太仓路 200 号上海医药大厦 1101 会议室以现场结合通讯方式召开。本次会议应 到董事九名，实到董事九名，符合《中华人民共和国公司法》和本公司章程关于 董事会召开法定人数的规定。本次会议由杨秋华董事长主持，监事和部分高级管 理人员列席本次会议。 二、董事会会议审议情况 表决结果：赞成 9 票，反对 0 票，弃权 0 票 本次会议审议并通过了以下议案： 本议案已提交公司第八届董事会独立董事专门会 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% compared to the market benchmark index within the next six months [6][17]. Core Insights - The company reported a revenue of 141.59 billion yuan (+1.6%) and a net profit attributable to shareholders of 4.459 billion yuan (+51.6%) for the first half of 2025. The significant net profit growth was primarily due to a one-time special gain of approximately 1.68 billion yuan from a change in accounting treatment for a joint venture [3][4]. - The commercial segment showed steady growth, with a revenue of 129.4 billion yuan (+2.2%) and a net profit of 1.79 billion yuan (+0.1%) in H1 2025. Notably, the innovative drug business achieved a revenue of 24.2 billion yuan (+22.6%) [4]. - The industrial segment's performance improved in Q2 2025, with a revenue of 12.16 billion yuan (-4.5%) and a net profit of 1.15 billion yuan (-12.3%) for H1 2025. The company is advancing multiple innovative drug pipelines, including NDA applications and clinical trials [5]. Financial Summary - The company adjusted its profit forecasts for 2025-2027, expecting net profits of 6.22 billion yuan, 4.99 billion yuan, and 5.5 billion yuan respectively, with corresponding P/E ratios of 11, 14, and 13 times [6][12]. - The financial data indicates a gross margin of 10.84% (-0.91 percentage points) and a net margin of 4.41% (+2.39 percentage points) for Q2 2025 [5][12]. - The company’s total revenue is projected to grow from 275.25 billion yuan in 2024 to 309.97 billion yuan in 2027, with a net profit forecasted to increase from 4.55 billion yuan in 2024 to 5.51 billion yuan in 2027 [7][12].

Core Insights - The pharmaceutical distribution market in China has shown steady growth, with a total sales scale exceeding 30 trillion yuan from 2019 to 2023, reflecting a year-on-year increase of 7.5% after excluding non-comparable factors [1][3]. Market Structure - The wholesale market dominates the pharmaceutical distribution sector, accounting for approximately 78% of the market share, while the retail market holds a 22% share [3]. Revenue Growth - The revenue of direct reporting pharmaceutical distribution enterprises reached 22,362 billion yuan in 2023, marking an 8% year-on-year increase after excluding non-comparable factors [5]. Accounts Receivable - The average accounts receivable days for pharmaceutical wholesale enterprises exceeded 150 days in 2023, with a reported average of 152 days, which is an increase of 2 days compared to 2022 [7]. Product Composition - Western medicine is the primary category in pharmaceutical sales, representing 68.7% of total sales, followed by traditional Chinese medicine at 15.5% and Chinese medicinal materials at 2.4%, collectively accounting for 86.6% of the market [9].

Core Insights - Shanghai Pharmaceuticals (601607.SH) reported a total operating revenue of 141.593 billion, ranking first among disclosed peers, with a year-on-year increase of 1.56% [1] - The net profit attributable to shareholders reached 4.459 billion, also ranking first among peers, reflecting a significant year-on-year increase of 51.56% [1] - The net cash flow from operating activities was 989 million, ranking fourth among peers, with a substantial year-on-year increase of 91.98% [1] Financial Metrics - The latest debt-to-asset ratio stands at 62.68%, a decrease of 0.17 percentage points from the same period last year [3] - The gross profit margin is reported at 10.55%, an increase of 0.29 percentage points from the previous quarter [3] - Return on equity (ROE) is at 5.94%, ranking fourth among peers, with a year-on-year increase of 1.73 percentage points [3] - The diluted earnings per share (EPS) is 1.20 yuan, ranking second among peers, with a year-on-year increase of 51.90% [3] - The total asset turnover ratio is 0.62 times, ranking seventh among peers [3] - The inventory turnover ratio is 3.17 times, ranking eleventh among peers [3] Shareholder Structure - The number of shareholders is 85,100, with the top five shareholders holding a total of 2.091 billion shares, accounting for 56.40% of the total share capital [3] - The top five shareholders are: 1. Shanghai Pharmaceuticals (Group) Co., Ltd. - 19.3% 2. Yunnan Baiyao Group Co., Ltd. - 17.9% 3. Shanghai Shun International Investment Co., Ltd. - 8.10% 4. Shanghai Shun (Group) Co., Ltd. - 5.98% 5. Shanghai Tandong Enterprise Consulting Service Co., Ltd. - 5.04% [3]

Core Viewpoint - The A-share market has seen a significant acceleration in the disclosure of 2025 semi-annual reports, with nearly 80% of listed companies having reported their results, highlighting mid-term dividends as a key feature this year [1][2]. Group 1: Company Performance - As of August 28, among the 4,593 companies that disclosed their semi-annual reports, 3,583 companies achieved profitability, representing 78% [3]. - Notable performances include: - China Galaxy reported a revenue of 13.747 billion yuan, a year-on-year increase of 37.71%, and a net profit of 6.488 billion yuan, up 47.86% [4]. - Semiconductor company Zhongwei reported a revenue of 4.961 billion yuan, a growth of 43.88%, and a net profit of 706 million yuan, up 36.62% [4]. - Shanghai Pharmaceuticals achieved a revenue of 141.593 billion yuan, a 1.56% increase, and a net profit of 4.459 billion yuan, up 51.56% [4]. - Yili reported a revenue of 61.777 billion yuan, a 3.49% increase, but a net profit decrease of 4.39% to 7.2 billion yuan [4]. Group 2: Industry Insights - The brokerage industry showed particularly strong performance, with several firms reporting impressive results despite market fluctuations [4]. - The liquor industry, however, displayed mixed results, with Shanxi Fenjiu reporting a revenue of 23.964 billion yuan, a 5.35% increase, but a net profit increase of only 1.13% [5]. - Water Well Square reported a revenue decrease of 12.84% to 1.498 billion yuan and a significant net profit drop of 56.52% [5]. Group 3: Dividend Announcements - As of August 28, the total announced dividend amount reached 334.2 billion yuan, with many companies disclosing their mid-term dividend plans [6][7]. - Companies like Huadian International and Nanshan Aluminum announced cash dividends of 1.045 billion yuan and 465 million yuan, respectively [6]. - China Petroleum announced a mid-term dividend of 0.22 yuan per share, totaling approximately 40.265 billion yuan [7]. - A total of 627 companies have announced dividends, indicating a trend towards higher frequency and quality of dividends, driven by regulatory encouragement [7][8].